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Background: Community-acquired pneumonia (CAP), a leading cause 
of mortality, mainly affects children in developing countries. The harsh 
circumstances experienced by refugees include various factors 
associated with respiratory pathogen transmission, and clinical 
progression of CAP. Consequently, the etiology of CAP in 
humanitarian crisis situations may differ to that of settled populations, 
which would impact appropriate case management. Therefore, the 
Pneumonia Etiology Among Refugees and the Lebanese population 
(PEARL) study was initiated with the objective of identifying the causal 
pathogenic microorganisms in the respiratory tract of children and 
adults from both the refugee and host country population presenting 
with signs of CAP during a humanitarian crisis. 
Methods: PEARL, a prospective, multicentric, case-control study, will 
be conducted at four primary healthcare facilities in Tripoli and the 
Bekaa valley over 15 months (including two high-transmission 
seasons/winters). Sociodemographic and medical data, and biological 
samples will be collected from at least 600 CAP cases and 600 
controls. Nasopharyngeal swabs, sputum, urine and blood samples 
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will be analyzed at five clinical pathology laboratories in Lebanon to 
identify the bacterial and viral etiological agents of CAP. 
Transcriptomic profiling of host leukocytes will be performed. 
Conclusions: PEARL is an original observational study that will provide 
important new information on the etiology of pneumonia among 
refugees, which may improve case management, help design 
antimicrobial stewardship interventions, and reduce morbidity and 
mortality due to CAP in a humanitarian crisis.
Keywords 
Community-Acquired Pneumonia, Lebanon, Refugees, Etiology, Case-
Control Studies, Epidemiology, Prevention & Control, Risk Factors
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Introduction
Lower respiratory tract infections (LRTI) are the second leading 
cause of mortality worldwide, accounting for an estimated 
2.8 million deaths annually, and mainly affect children in 
developing countries1. Community-acquired pneumonia (CAP) 
is caused by a variety of bacteria and viruses and is mainly 
characterized by lobar or broncho-pneumonic changes. However, 
identification of the etiology of pneumonia is often diffi-
cult, and optimal prevention and treatment strategies for CAP 
critically depend on a full understanding of its etiology. For 
example, intracellular (“atypical”) bacteria (Chlamydophila, 
Mycoplasma, etc.) require treatment with specific antibiotics, 
while purely viral infections do not. Furthermore, clinical exams, 
chest radiology and biological tests lack specificity, and blood 
cultures yield positive results in only 10 to 20% of cases.
Current interventions for CAP are primarily based on etio-
logical studies conducted in the early 1980s2–4, which indicated 
bacteria are responsible for almost half of all cases of CAP5,6; 
Streptococcus pneumoniae, Haemophilus influenzae and Staphy-
lococcus aureus were the most commonly identified bacteria. 
In children < 5-years-old, bacteria were responsible for severe 
forms of CAP: S. pneumoniae and H. influenzae accounted for 
approximately 60% of cases of severe and fatal pneumonia7,8 
and S. pneumoniae alone accounted for 11% of mortalities 
overall in children < 5-years-old9. However, other bacteria 
(e.g. Mycoplasma pneumoniae, Chlamydophila pneumoniae, 
Legionella pneumophila, Bordetella pertussis, etc.) may be 
responsible for a significant proportion of CAP10. Moreover, 
respiratory viruses such as influenza viruses, respiratory syncytial 
virus (RSV) and human metapneumovirus (hMPV) are known to 
make significant, often seasonal, contributions to CAP. Finally, 
superinfections, although poorly understood, are widely accepted 
to contribute to severe CAP. A clear picture of the etiology of CAP 
would help to estimate the potential impact of novel public health 
interventions, such as antiviral therapies in case management or 
influenza vaccination for prevention in vulnerable populations. In 
order to provide up-to-date data on the etiology of CAP, several 
studies were recently conducted, in particular two large studies 
in the USA in 2010–2012, targeting children and adults11,12, and 
two studies that targeted under-fives in low and middle income 
countries, the GABRIEL Pneumonia Study in 2010–2014, and 
the Pneumonia Etiology Research for Child Health (PERCH) 
study in 2011–201413. These studies pointed to the importance of 
viruses in the etiology of CAP.
LRTI are a major cause of morbidity and mortality in the acute 
phase of humanitarian crises. Case management (diagnoses, 
treatment choice and delivery) and public health interven-
tions (immunization strategies) for CAP in humanitarian crisis 
settings are conducted blindly or based on the assumption that 
evidence gathered in non-crisis settings applies to displaced 
populations. However, large knowledge gaps remain in many 
areas, including the etiology of these infections14,15. No studies 
have been specifically designed to assess the etiology of CAP 
in populations facing humanitarian crisis.
Evaluation of the etiology of infection
The reference method for identifying the pathogen responsible 
for an infection is to sample the infected tissues, i.e., the lung, in 
patients with pneumonia, and screen for pathogenic agents by 
culture or molecular tools. Such invasive procedures are difficult 
to set up, even in hospital settings, and virtually impossible in 
primary health care. To circumvent this issue, the causative agent 
can be identified using samples from the upper respiratory tract 
using non-invasive techniques, e.g. nasopharyngeal swabs11,12. 
Due to the existence of healthy carriers of several potential 
pathogens (e.g. Streptococcus pneumoniae) in the population, 
there is a need to adjust for carriage: the higher the proportion of 
asymptomatic carriers of a given pathogen, the lesser the 
chances that this agent is the etiology of CAP when found in the 
upper respiratory tract.
In the last decade, transcriptomic analyses of the blood of 
patients infected with different pathogens have revealed gene 
expression patterns that correlate strongly with individual 
etiologic agents16,17. White blood cells express different genes 
in response to infection with different agents, and these 
patterns can be used to distinguish viral and bacterial infections 
with high accuracy18. These transcriptomic patterns can even 
distinguish between different viral (or bacterial) infections, and 
also enable evaluation of the severity of infection. RNA sequenc-
ing analysis of the gene expression profiles of white blood cells 
during infection enables differentiation of viral and bacterial 
infections with higher specificity than white blood cell counts19. 
Therefore, transcriptomics represents an innovative tool that 
reduces the need to identify pathogens by culturing respira-
tory tract samples and does not need to be adjusted for asymp-
tomatic carriage. The ideal control samples for transcriptomic 
analysis are samples from healthy patients, i.e. those attending 
for vaccination or other routine healthcare visits.
Situation of Syrian refugees in Lebanon
Lebanon is severely affected by a complex, chronic and pro-
tracted refugee crisis due to the ongoing war in Syria that began 
in March 2011. The Bekaa valley is the main entry point for 
Syrian refugees, followed by the North Lebanon region and 
Beirut, with refugees settling all over the country. The crisis 
not only affects Syrian refugees, but also the local Lebanese 
population and Palestinian refugees who settled decades ago. 
            Amendments from Version 1
As compared with version 1, and thanks to the accurate remarks 
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The majority of Syrian refugees reside in approximately 4000 
informal tented settlements and mobile centers, garages and 
unfinished buildings, with no officially established access to 
food, water, sanitary means, health or education.
Respiratory tract infections (RTI) are among the leading causes 
of morbidity and mortality in children and adults affected by the 
current humanitarian crisis in Lebanon. According to Médecins 
Sans Frontières (MSF), RTI accounted for at least 56% of 
ambulatory or in-patient health care visits in the first six 
months of 2015, and up to 79% of visits among children under 
5-years-old in the healthcare facilities attended mainly by 
refugees in the Bekaa valley (MSF, personal communication). 
Unpublished data from primary healthcare facilities in Leba-
non suggests that 10–25% of these cases of RTI are CAP (Ali 
Ghassani, personal communication), though data on the etiology 
and severity of these cases of CAP cases is lacking.
In Lebanon, CAP peaks between October and April. Specifi-
cally, 80% of the primary consultations for children during 
winter are related to RTI, compared to 20% in the summer (Ali 
Ghassani, personal communication). The Lebanese surveillance 
program for pulmonary infections due to S. pneumoniae con-
siders the general population, and therefore current data on the 
incidence, predominant serotypes, and antimicrobial suscepti-
bility of CAP among the refugee population is not available20. 
UNICEF and the Lebanese Ministry of Health started the intro-
duction of a 13-valent pneumococcal vaccine (PCV) as part of a 
National Program in 2016, among children of Syrian, Palestinian 
and Lebanese origin.
Objectives
In order to fill the knowledge gaps described above, the 
Pneumonia Etiology Among Refugees and the Lebanese popula-
tion (PEARL) study was initiated in 2016 to identify the causal 
pathogenic microorganisms in the respiratory tract of children 
and adults presenting with signs of CAP to health facilities run by 
medical associations in the context of a humanitarian crisis. The 
first inclusions took place in November 2016, and the study is 
expected to last until March 2018.
The primary objective of the PEARL study is to estimate the 
population attributable fractions (PAFs) of specific viral and 
bacterial pathogens, i.e. the proportion of CAP attributable to 
each pathogen, in both the refugee population and Lebanese 
population. The goals behind this objective are (i) to enable 
local healthcare staff to provide more accurate diagnoses and 
improved case management and care, (ii) to help designing 
antimicrobial stewardship interventions, and (iii) to help assess-
ing the impact of PCV, as it will generate baseline data on 
the burden of CAP caused by Streptococcus pneumoniae at 
the introduction phase of PCV in the national vaccination 
program.
The secondary objectives of the PEARL study are to: identify 
S. pneumoniae serotypes in nasopharyngeal and blood samples; 
identify the antimicrobial susceptibility profiles of the patho-
genic bacteria isolated from nasopharyngeal and blood samples 
and compare these profiles with antibiotic prescriptions; examine 
the association between respiratory viral infections and inva-
sive pneumococcal infections; identify risk factors for CAP 
in this population, especially those that may be modifiable 
(crowding, tobacco smoking, domestic sources of smoke produced 
by cooking or heating, etc.), and thus provide data for preven-
tion programs; provide current data on the incidence and severity 
of CAP in vulnerable populations in Lebanon; provide a unique 
transcriptomics dataset as regards the sociodemographic profile 
of the patients and spectrum of diseases; compare microbiologi-
cal and transcriptomic methods in estimating viral vs bacterial 
attributable fractions of LRTI; and assess the operational capac-
ity of rapid, nuclear acid-based point-of-care diagnostic tests 
in a humanitarian crisis.
Protocol
Study setting and design
Based on refugee density, two main regions were selected for 
this multicentric prospective case-control study: the Bekaa valley 
and the city of Tripoli (Figure 1). Both regions have similar 
demographic composition, dynamics and climate. The popula-
tion eligible for the study consists of any child (>2-months-old) 
or adult attending one of four primary healthcare facilities (no 
hospital facilities) that provide routine health care and immu-
nization: one site located in Tripoli and three sites in the Bekaa 
valley (Kamed el Loz, Machghara, and Baalbeck El Ain). 
In addition to refugees, local and vulnerable Lebanese 
individuals who also attend these health centers (although to a 
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Nasopharyngeal, urine and blood samples will be collected 
from patients with CAP (cases). Adults with CAP able to produce 
sputum will be asked to provide a sputum sample.
As CAP-related pathogens can also be carried by healthy 
individuals, control individuals will be recruited from the same 
health facilities; cases and controls will be matched in a 1:1 ratio 
by age, season and site. Nasopharyngeal swabs and urine will be 
collected from all controls; a subset of controls (15%) will also 
be asked to provide a small blood sample (500–1000 µL) for 
transcriptomic analysis. Controls will not be asked to provide 
sputum samples.
After enrolment in the study, patients will be managed as per 
local guidelines and doctors’ recommendations; in particular, 
the study won’t alter procedures for referral for complementary 
examinations or hospitalization.
Inclusion criteria
Cases. Physicians will evaluate case definitions on the basis 
of a clinical examination and patient history. The case defini-
tion was based on WHO’s IMCI22. Cases should meet all of the 
following inclusion criteria: (i) patient aged > 2 months, (ii) 
with cough or dyspnea, (iii) lower chest wall indrawing (in chil-
dren ≤ 3 years only) or tachypnea, (iv) no wheezing sugges-
tive of asthma at auscultation, (v) onset of symptoms within the 
last 14 days, (vi) and informed consent statement signed by 
the patient, parent, or legal guardian (Supplementary File 1). 
Tachypnea is defined as > 50 breaths per minute in patients 
between 2-months and < 1-year-old; > 40 breaths per minute, 
between 1 and < 5-years-old; 30 breaths per minute, between 
≥ 5 and <18-years-old and > 20 breaths per minute, if ≥ 18 
years-old. Characteristics of wheezing suggestive of asthma 
included: expiratory wheezing, high pitched wheezing, wheez-
ing with history of asthma and without fever nor history of 
fever, and any clinical picture such as the clinician would 
exclude LRTI and retain asthma as final diagnostic.
Exclusion criteria are (i) any characteristic of healthcare- 
associated pneumonia, (including hospitalization at an acute care 
hospital for 2 or more days within 90 days of infection, residence 
in a nursing home or long-term care facility, recent intravenous 
antibiotic therapy, or wound care from medical staff within the 
30 days prior to the current infection); or (ii) increased risk of 
lower airway disease, such as immunocompromised status due 
to underlying disease, including hemodialysis, or immunosup-
pressant treatment; or (iii) treatment with inhaled corticosteroids 
or other asthma medications.
The study nurse will check inclusion criteria, and ask the patient 
or their parent/guardian to provide signed informed consent 
and fill in the case report form (CRF), which includes a medical 
history (e.g. HIV infection, tuberculosis, respiratory infec-
tions), risk factors for pneumonia, prior medical treatment and 
immunizations, description of clinical signs that warrant enrol-
ment in the study, current and recent treatment (antibiotic 
therapy), disease progression, and socio-economic characteristics 
(Supplementary File 2). Pulse oximetry is used to assess the 
severity of CAP23; pulse oximeters will be made available to 
all four healthcare facilities for the present study and pulse 
oximetry will be reported in the CRF. Data will be anonymized by 
attributing a unique patient identification code number issued at 
enrolment of each patient.
Physicians may request other tests such as chest radiography 
without interfering with the study protocol. Antimicrobial 
treatment may begin immediately after blood sampling, if 
required. Cases and controls may also undergo clinical and lab 
tests as required. Chest X-ray is not required as this examination 
is not available at all health care facilities, especially the three 
remote healthcare facilities in Bekaa valley; if available, results 
from chest X-rays will be reported in the CRF.
Severity of pneumonia will be classified according to the IMCI/
WHO guidelines22. Moreover, in children under five years 
of age, we will assess the breathing rate twice, since it has been 
shown that the cut-off of > 50 breaths per minute, assessed 
twice, is more specific for pneumonia than the standard IMCI 
recommendations for children 1–5 years old (40 breaths/min)24, 
and was successfully adopted in the ALMANACH protocol25,26.
Controls. An aged-matched control will be recruited for each 
case by age group (± 1 year for children aged 2 months to 
4 years, ± 2 years for children 5–17 years, and ± 5 years for 
patients aged 18–49 years old and adults aged ≥ 50 years old). 
Controls will be matched to cases attending the same site in the 
same calendar month (some flexibility is allowed since controls 
for cases included at the end of one month may be recruited in 
the next calendar month). The study nurse will identify next 
patient consulting for reasons other than respiratory (upper or 
lower respiratory tract) or gastrointestinal infection, check 
eligibility, obtain written informed consent from the participant, 
and fill in the CRF.
Controls should meet all of the following inclusion criteria: 
(i) patients aged > 2 months attending one of the four sites par-
ticipating in the study for symptomatic disease or immunization; 
and (ii) informed consent signed by patient or parent/guardian. 
Patients will be excluded as controls if they (i) exhibited any 
symptom of RTI (cough, dyspnea, chest wall indrawing, 
tachypnea, fever, coryzal symptoms/“cold”) or (ii) intestinal 
infection (watery/bloody diarrhea, abdominal cramps) in the last 5 
days. Individuals with gastro-intestinal symptoms were excluded 
as some viruses (adenovirus, enterovirus, and coronavirus) are 
proven or suspected to cause either respiratory or gastro-intestinal 
symptoms27–29, and including such patients as controls would 
result in an underestimation of the attributable fraction of these 
pathogens.
Sample size calculation
As pathogen distributions can vary according to patient age, 
the univariate and multivariate analyses will be stratified by age 
group. We calculated the total sample size required for each age 
group to detect a difference in pathogen prevalence between 
cases and controls (assuming an equal distribution of samples 
between the age groups) based on a power of 90% (α = 0.05). 
Pearson’s χ2 test indicated 150 cases and 150 controls were 
required in each of the four age strata (2 months to 4 years, 
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Blood Blood culture bottle +4°C Blood culture and AST Real time CH, LMSE
Tempus +4°C/-20°C Transcriptomics Batch NCH
EDTA tube +4°C WBC Real time EB, CH
+4°C/-80°C Triplex PCR Batch LRM, LMSE
Urine Sterile container  
(or sterile adhesive 
bags for babies)
+4°C Antibiotic activity* Batch LRM, LMSE
+4°C Binax Real time CH, LMSE
Nasopharyngeal swab Viral transport medium +4°C/-80°C Triplex PCR Batch LRM, LMSE
+4°C/-80°C Micro-array (BioFire)* Real time
+4°C/-80°C S. pneumo CAPS-PCR Batch
Nasopharyngeal swab STGG medium +4°C Bacterial culture* Real time CH, LMSE
+4°C/-80°C CAPS-PCR Batch LRM, LMSE
Sputum  
(adults only)
Sterile container +4°C Bacterial culture Real time CH, LMSE
+4°C/-80°C Triplex PCR Batch LRM, LMSE
+4°C/-80°C Micro-array (BioFire)* Real time
+4°C/-80°C S. pneumo CAPS-PCR Batch
*: assay also performed in controls; CH: Chtoura hospital; LMSE: Laboratoire Microbiologie Santé et Environnement; LRM: Laboratoire 
Rodolphe Mérieux; NCH: Nationwide Children’s Hospital; EB: El Bashaer health center.
5–17 years, 18–49 years, > 50 years) to detect a 15% differ-
ence in pathogen frequency between cases and controls (with 
a carriage prevalence < 10% in controls) or detect a difference 
in pathogen frequency of 20% (with a carriage prevalence of 
up to 30% in controls). If no differences between age groups is 
observed, pooling the data from age groups will increase statistical 
power.
Thus, the final sample size will be a minimum 600 cases and 
600 controls with the aim of including a maximum of 900 cases 
and 900 controls.
Analysis of biological samples
Biological samples will be collected and stored using standard 
protocols and transported together with the sample log to the 
laboratories in a multicentric manner (Table 1). All analytical 
tests will be performed according to good clinical laboratory 
practice (GCLP)30 following standard operating procedures 
defined for the study. Sample processing for cases and 
controls are illustrated in Figure 2 and Figure 3, respectively. 
The total volume of blood taken is 0.5-1.0 mL in controls of all 
ages and, in cases, 2.5-5.0 mL in infants (<1 year old), 3.5-6.0 
mL in children aged one to four, 10.5-17.0 and 6 mL in children 
aged five or above, and 18.5-19.0 mL in adults (≥18 years old), 
with a flexibility in the age cut-off depending on the individual’s 
weight and overall health status.
Clinically relevant results will be communicated to the clini-
cians in a timely manner. Such results include: (i) identification 
of pathogen bacteria in blood, by conventional microbiology or 
molecular tools, (ii) identification of clinically relevant bacte-
ria in nasopharyngeal swab or sputum of cases, e.g. detection 
of atypical bacteria; (iii) identification of RSV in infants (cases 
or controls) aged ≤12 months, and (iv) positive Binax® test 
in urine of case. Whenever the lab identifies a pathogen or 
sensitivity profile of importance for the clinical management 
of pneumonia, they will provide their etiological diagnosis to 
the clinical team to ensure appropriate case management. All 
laboratory data will also be transmitted to the local Fondation 
Mérieux office in Beirut.
Molecular biology testing of respiratory samples. A trained 
nurse or lab technician-in-charge will collect two nasopharyngeal 
samples from all cases and controls31: one will be discharged 
in virus transport medium (VTM) and the other in skim milk- 
tryptone-glucose-glycerol (STGG) medium. Nasopharyngeal 
swabs will be processed and analyzed as shown in Table 1 and 
Figure 2 and Figure 3.
Nucleic acids extracted from 350 µL of VTM using QIAamp® 
DNA mini kit (Qiagen, Hilden, Germany) will be subjected to a 
real-time triplex PCR assay targeting Streptococcus pneumo-
niae, Staphylococcus aureus and Haemophilus influenzae B, the 
three most common bacteria detected in CAP. This triplex PCR 
has been used in previous studies32,33. Briefly, 5 µL extracted 
nucleic acids are added to 9 µL Takyon No ROX Probe 2X 
MasterMix dTTP (Eurogentec, Seraing, Belgium) and 4 µL of a 
solution containing 1 µM of each primer and probe. Each PCR 
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Figure  3.  Sample  analysis  for  controls.  NP, nasopharyngeal; AST, Antimicrobial Susceptibility Testing; Caps PCR, capsular antigen 
serotyping PCR.
Figure 2. Sample analysis for cases. NP, nasopharyngeal; WBC, white blood cells; AST, Antimicrobial Susceptibility Testing; Caps PCR, 
capsular antigen serotyping PCR.
mixture is submitted to 95°C for 10 min then 40 cycles of 8 sec 
at 95°C then 34 sec at 60°C. The respective 5’-3’ sequences of 
forward primers, reverse primers and probes are: lytA gene 
(S. pneumoniae) ACG AAT AAC CAA CCA AAC AAC, CCA 
GTA GCC AGT GTC ATT C, and tca Atc Gtc Aag Ccg ttc t using 
HEX as a fluorophore (capital letter in probes indicate locked 
nucleic acid substitution); vicK gene (S. aureus) GAA GCA 
GTC TAA CCG TAG TC, GGG ATA TTA TAT ACC CAG ACA 
CG, and tcc Tta Cca Ccg Cca taa, using FAM as a fluorophore; 
bexA gene (H. influenzae B) ATT TGA GAA ACG CAA AGA 
Page 7 of 23
Gates Open Research 2019, 2:19 Last updated: 13 OCT 2020
CC, ATT TGA GAA ACG CAA AGA CC, and agt Ttc Aca Tag 
Ccc gag t, using Cy5 as a fluorophore. Amplification curves will 
be examined individually by two independent technicians, at the 
local laboratory and at the Laboratoire des Pathogènes Emergents 
(Lyon, France). Cycle thresholds (Ct) value will be manu-
ally set so that it intersects the exponential curve at its inflexion 
point. Any exponential signal observed between 0 and 40 Ct 
value will be considered as positive.
The FilmArray Respiratory Filmarray (BioFire Diagnostics, 
Salt Lake City, UT, USA) will be used to identify pathogens 
that cause pneumonia from VTM34 and sputum samples. The 17 
viruses and three atypical bacteria detected by this assay are 
adenovirus (ADV), coronavirus (CoV) HKU1, coronavirus NL63, 
coronavirus 229E, coronavirus OC43, hMPV, human rhinovirus 
(RV)/enterovirus (EV), influenza virus A (IVA), influenza 
A/H1, influenza A/H3, influenza A/H1-2009, influenza B, 
parainfluenza virus (PIV) 1, parainfluenza virus 2, parainfluenza 
virus 3, parainfluenza virus 4, RSV, Bordetella pertussis, 
Chlamydophila pneumoniae, and Mycoplasma pneumoniae. 
Samples from cases positive for Streptococcus pneumoniae by 
conventional microbiology or triplex PCR will be serotyped 
using a Multiplex Real-Time PCR assay35 that can identify 
40 capsular antigen serotypes (1, 2, 3, 4, 5, 6A/B, 6C, 7C, 7F, 8, 
9N/L, 9V, 10A, 10F, 11A, 12F, 13, 14, 15A, 15B/C, 16F, 17F, 18C, 
19A, 19F, 20, 21, 22F, 23A, 23B, 23F, 24, 31, 33F, 34, 35A, 35B, 
35F, 38, 39) and includes an internal control (LytA).
Culture of bacteria from respiratory samples. Sputum sam-
ples and STGG media will be inoculated onto different selective 
agar plates according to standard laboratory procedures (at least 
one blood culture medium, one chocolate agar, and one medium 
selective for gram-negative bacilli) and incubated under specific 
conditions (37°C, aerobic atmosphere supplemented with CO
2
) 
to determine the presence of respiratory pathogens and assess 
antibiotic susceptibility36. Quality of sputum and absence of con-
tamination by saliva will be assessed by standard laboratory 
procedures36. Positive cultures will be subjected to Gram stain-
ing and examined by light microscopy, and sub-cultured for 
identification and antimicrobial susceptibility testing if the strain 
is confirmed to be clinically relevant.
Detection of bacteria in blood. Duplicate aerobic haemoculture 
assays will be performed for all cases using BacT/ALERT 
(bioMérieux, Marcy l’Etoile, France) or BACTEC (Becton 
Dickinson, Franklin Lakes, NJ, USA) automated blood culture 
systems. The target blood volume for blood culture is 1-3 mL 
in under-fives and 6 mL in children aged five or above and in 
adults, following manufacturers’ recommendations. If the volume 
of blood recovered is insufficient to inoculate two bottles, a 
single culture will be performed. Positive cultures will be exam-
ined by light microscopy (Gram staining) and subcultured 
on agar culture media for identification. Antimicrobial sus-
ceptibility testing will be performed for all clinically relevant 
strains.
Whole blood (200 µL EDTA) samples from all cases will be 
extracted using QIAamp DNA blood mini kit (Qiagen, Hilden, 
Germany), and the same semi-quantitative multiplex Real-
Time PCR assay as for respiratory samples will be conducted on 
5 µL of extracted DNA to identify Streptococcus pneumoniae, 
Staphylococcus aureus and Haemophilus influenzae B.
Transcriptomics. Blood samples (0.5–1 mL) for transcriptomics 
from all cases and 15% of controls will be collected in Tempus 
tubes containing stabilizing agents for conservation of mRNA, and 
shipped to the Nationwide Children’s Hospital Research Institute, 
in Columbus, Ohio, USA. Sampling for transcriptomics was initi-
ated in May 2017.
Total RNA will be isolated from whole blood collected in Tem-
pus tube and analyzed for quality using the RNA 6000 Nano 
Kit (Agilent Technologies). Globin mRNAs will be further 
removed with GOBINclean kit (Thermo Fisher Scientific). 
Poly(A)-enriched next-generation sequencing library construc-
tion will be performed using the KAPA mRNA Hyper Prep 
Kit (KAPA Biosystems) with 500 ng of input total RNA and 
11 amplification cycles according to the manufacturer’s pro-
tocol. Individual libraries will be quantitated via quantitative 
PCR using the KAPA Library Quantification Kit, Universal 
(KAPA Biosystems) and equimolar pooled. Final pooled librar-
ies will be sequenced on an Illumina HiSeq 2500 with single- 
end 70-base-pair (bp) read lengths.
Urinalysis. The presence of antibiotics in urine samples 
from all cases and controls will be assessed using the disk 
diffusion method37, and the rapid immunochromatographic 
Binax® assay (Alere, Orlando, FL, USA) will be used for 
qualitative detection of S. pneumoniae C polysaccharide antigen 
in urine38.
Other data collected
All involved healthcare facilities will be required to provide 
monthly report of the total number of consultations and, when-
ever available, the number of LRTIs. This will help weighting 
the monthly results from the study to reflect the actual 
incidence of CAP. A subgroup of patients or parents/legal guard-
ians, randomly selected, was called back at least one month 
after inclusion to re-evaluate the outcome of included cases 
(hospitalization, death).
Study outcomes
The primary outcome of the PEARL study is the etiological 
distribution of CAP, expressed as PAFs for individual pathogenic 
agents. PAFs will be calculated for each three-month period of 
the 15-month study, and by patient age group (2 to 11-months-old 
and 1 to 4, 5 to 17, 18 to 49, and ≥ 50-years-old), by site 
location (Tripoli vs. Bekaa valley), subpopulation (Syrian 
refugees versus Lebanese population), and severity of pneumonia.
Additional indicators will be examined to assist data interpreta-
tion and for public health and clinical care purposes, including 
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the incidence of RTI and other diseases in the populations 
consulting the four healthcare facilities involved in the study, 
agent-specific hospitalization and fatality rates, the socio-
demographic characteristics of the patients, clinical signs of 
CAP (e.g. severity criteria), epidemic features if appropri-
ate (e.g. types of influenza viruses circulating during epidemic 
periods), and care provided (e.g. antimicrobial use).
Data management and analysis
All data (CRF, informed consent forms, data logs) will be 
transmitted to the local Fondation Mérieux office in Beirut for 
data entry using EpiInfo version 7.2 (CDC, Atlanta, GA, USA). 
The data will be anonymized by attributing a unique patient 
identification code number issued at patient enrolment. Access 
to the names of participants and their corresponding identifica-
tion codes will be restricted and forms will be secured in locked 
cupboards.
Data analyses will include (i) descriptive comparisons of the 
sociodemographic, clinical, and lab data of cases and controls; 
(ii) univariate/multivariate logistic regression of the relation-
ship between case/control status and pathogens, adjusted for age, 
season, site, and pneumonia risk factors; and (iii) computation 
of PAFs for every pathogen, specified by age group, period, 
study site, subpopulation (Syrian refugees, or general Lebanese 
population), and pneumonia severity, as described previously39. 
Ninety-five-percent confidence intervals will be calculated, with 
regards to the outcomes linked to the primary and secondary 
objectives. Analyses will be performed using R version 3.3.2 (R 
Core Team, Vienna, Austria40) and/or Stata version 13.0 (Stata-
Corp LP, College Station, TX, USA) software. RNA sequenc-
ing data from transcriptomics will be analyzed at the Nationwide 
Children’s Hospital, OH, USA. Quality control of raw reads 
will be performed with FASTQC. Reads will be aligned to 
the reference human genome (GRCh38) using hisat2 after qual-
ity and adapter trimming by cutadapt. FeatureCounts program 
will be used to quantify total number of read counts for each 
gene. The RNA sequencing data analysis will be performed in 
the R programming language, using DESeq2 R package for size 
factor, dispersion estimation calculation and differential gene 
expression analysis. A number of supervised and unsupervised 
analytical approaches, and modular analyses will be used to iden-
tify the pathogen-associated transcriptome profiles as previously 
described41–43. Etiologic fractions will be also computed from 
transcriptomics data, independently from calculations from 
microbiological data, and compared with each other.
Dissemination of the study outcomes
The results of the study (microbiological and transcriptomics 
results) will be published as scientific publications in interna-
tional peer-reviewed journals. The designation of co-authors 
will conform to international guidelines governing publications.
The findings of the project, when completed, will be presented 
to the Ministry of Health of Lebanon, and to the medical and 
scientific community, such as United Nations agencies and 
non-governmental organizations, involved in medical care of 
vulnerable populations in Lebanon. The results will also be 
communicated via the GABRIEL website (https://www.gabriel-
network.org/). The study data relevant to a publication authored 
by the investigators will be available for review in a public data 
repository
Ethical considerations
This study will be conducted in accordance with the Declara-
tion of Helsinki44, the recommendations for Good Ethical Prac-
tices in Epidemiology of the Association of French-language 
Epidemiologists45, the Good Clinical Practice recommenda-
tions from the International Conference on Harmonization of 
Technical Requirements for Registration of Pharmaceuticals for 
Human Use (ICH) relevant to observational studies46, and the 
GCLP guidelines of the WHO30. The informed consent statement 
has been translated into Arabic and was validated during the 
pilot phase of the study. All adult patients and the parents or 
legal guardians of children (i.e. ≤18 years) will be asked to sign 
an informed consent statement prior to enrolment in the study.
As no national ethic committee exists in Lebanon, the study 
protocol and all other documents related to the trial (informed 
consent, CRFs, amendments) have been approved by the 
institutional review boards of the following organizations: 
El Bashaer Association, Tripoli, Lebanon (5th December 
2015); Université Libanaise, Ecole doctorale des Sciences et 
Technologies, Tripoli, Lebanon (3rd December 2015); Amel 
Association, Beirut, Lebanon (9th December 2015); and Université 
Saint-Joseph, Beirut, Lebanon (10th November 2016).
Current status of the study
Patient enrollment began in November 2016 and was com-
pleted in March 2018. At the time of submission of the 
first version of the manuscript, data cleaning and analysis 
was ongoing.
Discussion/conclusions
The Pneumonia Etiology Among Refugees and Lebanese popu-
lation (PEARL) study will yield unique data on the etiology of 
CAP in the context of a humanitarian crisis. This study is not 
only original in terms of target population (refugees), but also 
as it will assess patients of all ages and adopt a primary health 
care approach while previous major studies only targeted hospital-
ized cases2–5,7,13. Therefore, this study may provide a unique and 
valuable perspective on the etiology of CAP in the context of a 
humanitarian crisis.
However, assessment of the etiology of CAP in low resource 
primary health care settings relies on clinical signs for case 
definition, as chest X-rays are not available at most of the 
centers in this study. Inclusion criteria for cases of pneumonia are 
a controversial issue. Several case definitions, based on differ-
ent clinical, radiological, or biological criteria, have been used in 
different studies. Opting for a single case definition imposes 
restrictions on the anatomical and histological levels of the 
respiratory tract involved, on the severity of disease, and 
therefore may introduce a bias towards the relative prevalence 
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or contribution of specific pathogens. This makes it difficult to 
compare results between studies using different case definitions; 
the present study does not avoid this limitation.
We also anticipate other limitations. For example, the imperfect 
sensitivity of the diagnostic tests used to identify certain 
pathogens may result in an underestimation of certain etiological 
fractions47. Moreover, with regards to surveillance of pneumo-
nia, given that the population covered by the healthcare facili-
ties participating in this study is hard to define, estimation of the 
precise incidence of CAP in this population might not be possi-
ble. Additionally, certain aspects of CAP will not be explored 
in this study, especially AIDS-associated pneumonia and tuber-
culosis. We expect individuals with HIV will be excluded from 
the present study as HIV infection is one type of immunosup-
pression, which is an exclusion criterion. As the prevalence of 
HIV is very low (< 0.1%) in both the general Lebanese and Syr-
ian populations48, inclusion of cases HIV/AIDS-associated 
CAP would only have a small effect on the results. Patients with 
tuberculosis are also expected to be excluded, since duration 
of symptoms >14 days is an exclusion criterion. The incidence 
rate of tuberculosis among Syrian refugees did not increase in 
the last couple of years and remains relatively low at close to 
pre-war levels, i.e. 10-20/100.000 population49. Therefore, we 
consider it unlikely that tuberculosis is a major cause of acute 
LRTI in our population50.
Finally, the external validity of our study is limited in time (15 
months) and space (four health facilities). A case-control study 
cannot replace longitudinal surveillance systems, as are currently 
being set up in Lebanon, e.g. the Lebanese Inter-Hospital 
Pneumococcal Surveillance Program20. Therefore, although 
the situation of Syrian refugees in Lebanon shares a lot of 
characteristics with other crises, one should be cautious about 
applying the results of PEARL to other humanitarian crises, 
because of the variations of the epidemiology of LRTI.
Despite these limitations, the PEARL study is expected to 
provide healthcare planners with an empirical basis for the 
management of CAP in the context of a refugee crisis. Such 
information may help to guide population-based health inter-
ventions, such as immunization strategies for pneumococci, 
H. influenzae and influenza. In particular, analysis of S. pneumo-
niae serotypes in vaccinated and non-vaccinated individuals will 
provide information on the herd effect following introduction 
of the PCV in Lebanon and will provide proxy baseline data 
for evaluation of the success of this vaccination program. This 
study will also provide practical experience and a methodology 
for determination of the etiology and involvement of viral and 
bacterial agents in CAP in other similar humanitarian crisis 
settings.
Data availability
No data is associated with this article.
Grant information
This project is supported by the Bill and Melinda Gates Foundation 
[OPP1168739] and the Fondation Mérieux. 
The funders had no role in study design, data collection and 
analysis, decision to publish, or preparation of the manuscript.
Acknowledgements
We would like to thank all of the participants in this study, 
who provided their time and biological samples. We are very 
grateful to all health care workers, nurses, medical doctors and 
laboratory technicians at the participating health facilities, in 
particular: Ahmad Al Hallak, Anas Altabaa, Ali Rida, Asma 
Allouch, Danielle Chaaya, Hossam Al Nazer, Hussein Madie, 
Khaled Hallak, Majdeddine Mouzawak, Marianne Abi Fadel, 
Maryam Menhem, Nahed Elboosh, Souraya Nasser, Taha Abdou, 
Yasmine Amraoui, Zeina Jbara, and the other individuals who 
helped to set up this protocol. Khaled S. Aoun, Kamile, and 
especially Shafiq Bassil from Bioteck company deserve a 
special note for their kind collaboration in the transportation of 
biological samples. We thank Rana Hajjeh, Abdullah Brooks 
and Keith Klugman for their careful review of the protocol. 
Editorial support was provided by Andrea Devlin of Science 
Editing Experts.
PEARL Study Group members: Valentina Abdel Khelek 
(Amel Association, Lebanon), Mohammad Alabrash (Al-Bashaer 
Medical Center, Lebanon), Ghadban Al Ghadban (Amel Asso-
ciation), Mohamad Al Zayed (Amel Association), Cynthia 
Bakkalian (Fondation Mérieux, France), Zeinab Farhat (Amel 
Association), Ahmad Obeid (Al-Bashaer Medical Center), Pierre 
Salloum (Bioteck, Lebanon), Haneen Saty (Amel Association).
Supplementary material
Supplementary File 1: Informed consent form.
Click here to access the data.
Supplementary File 2: Case report form.
Click here to access the data.
Page 10 of 23
Gates Open Research 2019, 2:19 Last updated: 13 OCT 2020
References
1. Lozano R, Naghavi M, Foreman K, et al.: Global and regional mortality from 235 
causes of death for 20 age groups in 1990 and 2010: a systematic analysis for 
the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859): 2095–128. 
PubMed Abstract | Publisher Full Text 
2. Shann F: Etiology of severe pneumonia in children in developing countries. 
Pediatr Infect Dis. 1986; 5(2): 247–52.  
PubMed Abstract 
3. Wall RA, Corrah PT, Mabey DC, et al.: The etiology of lobar pneumonia in the 
Gambia. Bull World Health Organ. 1986; 64(4): 553–8.  
PubMed Abstract | Free Full Text 
4. Ikeogu MO: Acute pneumonia in Zimbabwe: bacterial isolates by lung 
aspiration. Arch Dis Child. 1988; 63(10): 1266–7.  
PubMed Abstract | Publisher Full Text | Free Full Text 
5. Scott JA, Hall AJ, Muyodi C, et al.: Aetiology, outcome, and risk factors for 
mortality among adults with acute pneumonia in Kenya. Lancet. 2000; 
355(9211): 1225–30.  
PubMed Abstract | Publisher Full Text 
6. Scott JA, Brooks WA, Peiris JS, et al.: Pneumonia research to reduce childhood 
mortality in the developing world. J Clin Invest. 2008; 118(4): 1291–300.  
PubMed Abstract | Publisher Full Text | Free Full Text 
7. Rudan I, Boschi-Pinto C, Biloglav Z, et al.: Epidemiology and etiology of 
childhood pneumonia. Bull World Health Organ. 2008; 86(5): 408–16.  
PubMed Abstract | Publisher Full Text | Free Full Text 
8. GBD 2015 LRI Collaborators: Estimates of the global, regional, and national 
morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 
countries: a systematic analysis for the Global Burden of Disease Study 2015. 
Lancet Infect Dis. 2017; 17(11): 1133–61.  
PubMed Abstract | Publisher Full Text | Free Full Text 
9. O’Brien KL, Wolfson LJ, Watt JP, et al.: Burden of disease caused by 
Streptococcus pneumoniae in children younger than 5 years: global 
estimates. Lancet. 2009; 374(9693): 893–902.  
PubMed Abstract | Publisher Full Text 
10. Castriota-Scanderbeg A, Popolizio T, Sacco M, et al.: [Diagnosis of mycoplasma 
pneumonia in children: which is the role of thoracic radiography?]. Radiol Med. 
1995; 89(6): 782–6.  
PubMed Abstract 
11. Jain S, Williams DJ, Arnold SR, et al.: Community-acquired pneumonia requiring 
hospitalization among U.S. children. N Engl J Med. 2015; 372(9): 835–45. 
PubMed Abstract | Publisher Full Text | Free Full Text 
12. Jain S, Self WH, Wunderink RG, et al.: Community-Acquired Pneumonia 
Requiring Hospitalization among U.S. Adults. N Engl J Med. 2015; 373(5): 
415–27.  
PubMed Abstract | Publisher Full Text | Free Full Text 
13. Levine OS, O’Brien KL, Deloria-Knoll M, et al.: The Pneumonia Etiology Research 
for Child Health Project: a 21st century childhood pneumonia etiology study. 
Clin Infect Dis. 2012; 54 Suppl 2: S93–101.  
PubMed Abstract | Publisher Full Text | Free Full Text 
14. Connolly MA, Gayer M, Ryan MJ, et al.: Communicable diseases in complex 
emergencies: impact and challenges. Lancet. 2004; 364(9449): 1974–83. 
PubMed Abstract | Publisher Full Text 
15. Blanchet K, Ramesh A, Frison S, et al.: Evidence on public health interventions 
in humanitarian crises. Lancet. 2017; 390(10109): 2287–96.  
PubMed Abstract | Publisher Full Text 
16. Mejias A, Suarez NM, Ramilo O: Detecting specific infections in children 
through host responses: a paradigm shift. Curr Opin Infect Dis. 2014; 27(3): 
228–35.  
PubMed Abstract | Publisher Full Text | Free Full Text 
17. Zaas AK, Chen M, Varkey J, et al.: Gene expression signatures diagnose 
influenza and other symptomatic respiratory viral infections in humans. Cell 
Host Microbe. 2009; 6(3): 207–17.  
PubMed Abstract | Publisher Full Text | Free Full Text 
18. Ramilo O, Mejías A: Shifting the paradigm: host gene signatures for diagnosis 
of infectious diseases. Cell Host Microbe. 2009; 6(3): 199–200.  
PubMed Abstract | Publisher Full Text 
19. Hu X, Yu J, Crosby SD, et al.: Gene expression profiles in febrile children with 
defined viral and bacterial infection. Proc Natl Acad Sci U S A. 2013; 110(31): 
12792–7.  
PubMed Abstract | Publisher Full Text | Free Full Text 
20. Hanna-Wakim R, Chehab H, Mahfouz I, et al.: Epidemiologic characteristics, 
serotypes, and antimicrobial susceptibilities of invasive Streptococcus 
pneumoniae isolates in a nationwide surveillance study in Lebanon. Vaccine. 
2012; 30 Suppl 6: G11–7.  
PubMed Abstract | Publisher Full Text 
21. UNHCR: Refugees from Syria: Lebanon. 2015.  
Reference Source
22. World Health Organization, UNICEF: Integrated Management of Childhood 
Illness. Geneva. 2014.  
Reference Source
23. Plüddemann A, Thompson M, Heneghan C, et al.: Pulse oximetry in primary care: 
primary care diagnostic technology update. Br J Gen Pract. 2011; 61(586): 
358–9.  
PubMed Abstract | Publisher Full Text | Free Full Text 
24. Rambaud-Althaus C, Althaus F, Genton B, et al.: Clinical features for diagnosis 
of pneumonia in children younger than 5 years: a systematic review and meta-
analysis. Lancet Infect Dis. 2015; 15(4): 439–50.  
PubMed Abstract | Publisher Full Text 
25. Rambaud-Althaus C, Shao AF, Kahama-Maro J, et al.: Managing the Sick Child 
in the Era of Declining Malaria Transmission: Development of ALMANACH, an 
Electronic Algorithm for Appropriate Use of Antimicrobials. PLoS One. 2015; 
10(7): e0127674.  
PubMed Abstract | Publisher Full Text | Free Full Text 
26. Shao AF, Rambaud-Althaus C, Samaka J, et al.: New Algorithm for Managing 
Childhood Illness Using Mobile Technology (ALMANACH): A Controlled Non-
Inferiority Study on Clinical Outcome and Antibiotic Use in Tanzania. PLoS 
One. 2015; 10(7): e0132316.  
PubMed Abstract | Publisher Full Text | Free Full Text 
27. Wilhelmi I, Roman E, Sánchez-Fauquier A: Viruses causing gastroenteritis. Clin 
Microbiol Infect. 2003; 9(4): 247–62.  
PubMed Abstract | Publisher Full Text 
28. Zhou HT, Yi HS, Guo YH, et al.: Enterovirus-related diarrhoea in Guangdong, 
China: clinical features and implications in hand, foot and mouth disease and 
herpangina. BMC Infect Dis. 2016; 16: 128.  
PubMed Abstract | Publisher Full Text | Free Full Text 
29. Romero JR, Rotbart HA: Enteroviruses. In: Murray PR, Baron EJ, Jorgensen 
JH, Pfaller MA, Yolken RH, editors. Manual of Clinical Microbiology. 8th edition. 
Washington, DC: ASM Press; 2003; 1427–38. 
30. World Health Organization: Good clinical laboratory practice (GCLP). Geneva: 
World Health Organization on behalf of the Special Programme for Research and 
Training in Tropical Diseases; 2009.  
Reference Source
31. World Health Organization: WHO guidelines for the collection of human 
specimens for laboratory diagnosis of avian influenza infection [Internet]. 
2005; Accessed: 2016-03-16. (Archived by WebCite® at  
http://www.webcitation.org/6g33epwmS). 
Reference Source
32. Albrich WC, Madhi SA, Adrian PV, et al.: Pneumococcal colonisation density: a 
new marker for disease severity in HIV-infected adults with pneumonia. BMJ 
Open. 2014; 4(8): e005953.  
PubMed Abstract | Publisher Full Text | Free Full Text 
33. Albrich WC, Madhi SA, Adrian PV, et al.: Genomic load from sputum samples 
and nasopharyngeal swabs for diagnosis of pneumococcal pneumonia in HIV-
infected adults. J Clin Microbiol. 2014; 52(12): 4224–9.  
PubMed Abstract | Publisher Full Text | Free Full Text 
34. Babady NE: The FilmArray® respiratory panel: an automated, broadly 
multiplexed molecular test for the rapid and accurate detection of respiratory 
pathogens. Expert Rev Mol Diagn. 2013; 13(8): 779–88.  
PubMed Abstract | Publisher Full Text 
35. Messaoudi M, Milenkov M, Albrich WC, et al.: The Relevance of a Novel 
Quantitative Assay to Detect up to 40 Major Streptococcus pneumoniae 
Serotypes Directly in Clinical Nasopharyngeal and Blood Specimens. PLoS 
One. 2016; 11(3): e0151428.  
PubMed Abstract | Publisher Full Text | Free Full Text 
36. Thomson RBJ, Miller JM: Specimen Collection, Transport, and Processing: 
Bacteriology. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, 
editors. Manual of Clinical Microbiology. 8th edition. Washington, DC: ASM Press; 
2003; 286–330.
37. Driscoll AJ, Bhat N, Karron RA, et al.: Disk diffusion bioassays for the detection 
of antibiotic activity in body fluids: applications for the Pneumonia Etiology 
Research for Child Health project. Clin Infect Dis. 2012; 54 Suppl 2: S159–64. 
PubMed Abstract | Publisher Full Text 
38. Smith MD, Derrington P, Evans R, et al.: Rapid diagnosis of bacteremic 
pneumococcal infections in adults by using the Binax NOW Streptococcus 
pneumoniae urinary antigen test: a prospective, controlled clinical evaluation. 
J Clin Microbiol. 2003; 41(7): 2810–3.  
PubMed Abstract | Publisher Full Text | Free Full Text 
39. Bénet T, Sánchez Picot V, Messaoudi M, et al.: Microorganisms Associated 
With Pneumonia in Children < 5 Years of Age in Developing and Emerging 
Countries: The GABRIEL Pneumonia Multicenter, Prospective, Case-Control 
Study. Clin Infect Dis. 2017; 65(4): 604–12.  
PubMed Abstract | Publisher Full Text 
40. R Core Team: R: A Language and Environment for Statistical Computing. 
Vienna, Austria; 2016. 
41. Mejias A, Dimo B, Suarez NM, et al.: Whole blood gene expression profiles to 
assess pathogenesis and disease severity in infants with respiratory syncytial 
virus infection. PLoS Med. 2013; 10(11): e1001549.  
PubMed Abstract | Publisher Full Text | Free Full Text 
42. Suarez NM, Bunsow E, Falsey AR, et al.: Superiority of transcriptional profiling 
over procalcitonin for distinguishing bacterial from viral lower respiratory 
tract infections in hospitalized adults. J Infect Dis. 2015; 212(2): 213–22. 
PubMed Abstract | Publisher Full Text | Free Full Text 
Page 11 of 23
Gates Open Research 2019, 2:19 Last updated: 13 OCT 2020
43. Wallihan RG, Suárez NM, Cohen DM, et al.: Molecular Distance to Health 
Transcriptional Score and Disease Severity in Children Hospitalized With 
Community-Acquired Pneumonia. Front Cell Infect Microbiol. 2018; 8: 382. 
PubMed Abstract | Publisher Full Text | Free Full Text
44. World Medical Association: Declaration of Helsinki - Ethical Principles for 
Medical Research Involving Human Subjects. Fortaleza; 2013.  
Reference Source
45. Association des Epidémiologistes de Langue Française: Recommandations 
de Déontologie et de Bonnes Pratiques en Epidémiologie. Bordeaux; 2007. 
Reference Source
46. International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use. Good Clinical Practice. 1997. 
47. Hammitt LL, Feikin DR, Scott JAG, et al.: Addressing the Analytic Challenges 
of Cross-Sectional Pediatric Pneumonia Etiology Data. Clin Infect Dis. 2017; 
64(suppl_3): S197–204.  
PubMed Abstract | Publisher Full Text | Free Full Text 
48. Bozicevic I, Riedner G, Haghdoost A: HIV case reporting in the countries of 
North Africa and the Middle East. J Int AIDS Soc. 2014; 17(1): 18962.  
PubMed Abstract | Publisher Full Text | Free Full Text 
49. Ismail MB, Rafei R, Dabboussi F, et al.: Tuberculosis, war, and refugees: 
Spotlight on the Syrian humanitarian crisis. Leong JM, editor. PLOS Pathog. 
2018; 14(6): e1007014.  
PubMed Abstract | Publisher Full Text | Free Full Text 
50. Bellos A, Mulholland K, O’Brien KL, et al.: The burden of acute respiratory 
infections in crisis-affected populations: a systematic review. Confl Health. 
2010; 4: 3.  
PubMed Abstract | Publisher Full Text | Free Full Text 
Page 12 of 23
Gates Open Research 2019, 2:19 Last updated: 13 OCT 2020
Open Peer Review
Current Peer Review Status:    
Version 2
Reviewer Report 13 October 2020
https://doi.org/10.21956/gatesopenres.14036.r29789
© 2020 King C. This is an open access peer review report distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited.
Carina King   
Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden 
This presents a clear study protocol, aiming to answer an important (but challenging!) question - 
of LRTI aetiology in a humanitarian setting.  
 
Background:
Can you also provide information on vaccine coverage (if it can be disaggregated?), and 
influenza vaccine policies?  
 
○
Indicate what formulation of PCV.○
 
Protocol:
Why was chest indrawing only considered for children <=3 years? 
 
○
Can you provide a bit more information on whether pulse oximetry was new in this setting, 
and if so, what training was done and quality control? 
 
○
It wasn't clear whether you intend to use the averaged RR over two counts, or just one. And 
whether this will be done for all age groups.  
 
○
Will any analyses of multi-pathogen versus single pathogen presentation be done? Thinking 
of the PERCH findings, where this was an important result? 
○
 
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
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Yes
Are the datasets clearly presented in a useable and accessible format?
Not applicable
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Infectious epidemiology, paediatric pneumonia
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard.
Reviewer Report 14 January 2020
https://doi.org/10.21956/gatesopenres.14036.r27382
© 2020 Page A. This is an open access peer review report distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited.
Anne-Laure Page  
Epicentre, Paris, France 
I have reviewed the response from the authors and believe that the revisions are appropriate.
 
Is the rationale for, and objectives of, the study clearly described?
Not applicable
Is the study design appropriate for the research question?
Not applicable
Are sufficient details of the methods provided to allow replication by others?
Not applicable
Are the datasets clearly presented in a useable and accessible format?
Not applicable
Competing Interests: No competing interests were disclosed.
I confirm that I have read this submission and believe that I have an appropriate level of 




Page 14 of 23
Gates Open Research 2019, 2:19 Last updated: 13 OCT 2020
Reviewer Report 26 November 2018
https://doi.org/10.21956/gatesopenres.13878.r26432
© 2018 Howie S. This is an open access peer review report distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited.
Stephen R. Howie  
Department of Paediatrics: Child and Youth Health,  University of Auckland, Auckland, New 
Zealand 
Thank you for the opportunity to review this study protocol. This protocol describes a multicentre 
case control study of pneumonia etiology in refugee populations in Lebanon. This is a population 
at high risk of pneumonia and data on etiology in this group will be welcome. The study has 
already completed recruitment, and is undergoing analysis. It is no simple task undertaking such a 
study, and I look forward to seeing its findings. 
  
I have a number of comments and suggestions. The protocol is clear in some of its aspects and 
unclear in others: I commend the authors for the former and I will focus my comments on the 
latter, which are points to be addressed. 
  
The authors rightly stress the limitations of ‘blindly’ applying etiology data from other studies to 
this population. They should be similarly cautious about applying their findings to those suffering 
in the midst of humanitarian crisis elsewhere, and even to those in the study settings at other 
times.  Fifteen months is relatively short, and refugee contexts are unstable and prone to 
epidemics. What happens in that 15 month period may not be what is happening the next year.  A 
case-control study such as this certainly has value, and longitudinal surveillance would add more 
value. The relationship between existing pneumococcal surveillance systems in Lebanon and this 
study is not clear from the protocol; adding broader pathogen surveillance to those systems has 
much to recommend it. I note too the lack of any data about TB in the study protocol, a gap it 
would be good to fill. Are there plans to address this in the future? 
  
The protocol makes much of the benefits of transcriptomic analysis (including that it ‘reduces the 
need to identify pathogens by culturing respiratory tract samples’) but is relatively silent on how 
this will be undertaken and how data will be used to achieve the primary aims.  Biomarkers for 
pneumonia etiology (whether they be transcriptomic or other), while attractive conceptually, have 
many limitations, and their practical applicability at this point need careful scrutiny. I wonder 
whether the transcriptomic aspect of this study is an exploratory add-on (not in itself an invalid 
thing to do). I see no mention of power calculations with respect to the transcriptomic element, 
for instance, or how it will be integrated into the analysis as a whole.   
 
The power calculation description is restricted to the primary objective. It would be helpful to 
show that there is adequate power for all objectives.  
  
The analytic methods planned for the primary objective are fairly restricted.  I would encourage 
the authors to learn from the approaches taken in studies such as PERCH and get the most they 
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can out of the data. This can still be done even though recruitment has been completed. 
  
There is no mention of using a point-of-care testing approach except at the end of the objectives 
and I wonder what was meant by that. 
  
The case definition used was not explicitly linked to the WHO definition, but reference was made 
to using WHO categorisation of severity.   Clarifying the relationship between study and WHO 
definitions would be helpful.   
  
What does the protocol mean when it says that inclusion requires “no wheezing suggestive of 
asthma at auscultation”? What sort of wheezing is that? Does ‘suggestive’ mean age, history, trial 
of bronchodilator, or something else?  What does the protocol mean when it specifies “particular 
attention to pneumonia with a breathing rate > 50 breaths per minute’? Was this a de facto entry 
criterion?  
  
What does the protocol mean when it says that ‘relevant’ results will be communicated to 
clinicians. Which are these? Did you share NP or sputum PCR results and if so how did you suggest 
that clinicians interpret them? 
  
The protocol appears to state that 6ml of blood will be taken for blood culture. Even in 
infants? The sample collection protocols requires clarification here.  
 
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Partly
Are sufficient details of the methods provided to allow replication by others?
Partly
Are the datasets clearly presented in a useable and accessible format?
Not applicable
Competing Interests: Dr. Howie has a patent 'Lipocalin-2 as a Biomarker for Pneumococcal 
Infection Status'  pending, which is not of specific relevance to this article but of broad relevance 
to the subject of pneumonia aetiology. No other competing interests were disclosed.
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
Author Response 01 Mar 2019
Thomas Kesteman, Fondation Mérieux, Lyon, France 
We would like to express thanks the reviewer for his useful comments and suggestions. We 
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carefully reviewed his report and we changed the manuscript according to his propositions. 
Our answers to his questions and comments are listed in the text below. 
 
Comment: The authors rightly stress the limitations of ‘blindly’ applying etiology data from 
other studies to this population. They should be similarly cautious about applying their 
findings to those suffering in the midst of humanitarian crisis elsewhere, and even to those 
in the study settings at other times.  
Action/Answer: We added a sentence in the paragraph regarding the limitations of the 
study (Discussion chapter): “although the situation of Syrian refugees in Lebanon shares a lot 
of characteristics with other crises, one should be cautious about applying the results of 
PEARL to other humanitarian crises, because of the variations of the epidemiology of LRTI.” 
 
Comment: Fifteen months is relatively short, and refugee contexts are unstable and prone 
to epidemics. What happens in that 15 month period may not be what is happening the 
next year.  A case-control study such as this certainly has value, and longitudinal 
surveillance would add more value. The relationship between existing pneumococcal 
surveillance systems in Lebanon and this study is not clear from the protocol; adding 
broader pathogen surveillance to those systems has much to recommend it. 
Action/Answer: We added a sentence in the Discussion, just before the one above: “Finally, 
the external validity of our study is limited in time (15 months) and space (four health 
facilities). A case-control study cannot replace longitudinal surveillance systems, as are 
currently being set up in Lebanon, e.g. the Lebanese Inter-Hospital Pneumococcal 
Surveillance Program.”. 
 
Comment: I note too the lack of any data about TB in the study protocol, a gap it would be 
good to fill. Are there plans to address this in the future? 
Action/Answer: This was acknowledged as a limitation of our study in the first version of 
the manuscript: “certain aspects of CAP will not be explored in this study […]. Patients with 
tuberculosis are expected to be excluded, since duration of symptoms >14 days is an 
exclusion criterion.” Nevertheless, we added the following sentence: “The incidence rate of 
tuberculosis among Syrian refugees did not increase in the last couple of years and remains 
relatively low at close to pre-war levels, i.e. 10-20/100.000 population. Therefore, we 
consider it unlikely that tuberculosis is a major cause of acute LRTI in our population.” and 
we provided references for this assertion. 
 
Comment: The protocol makes much of the benefits of transcriptomic analysis (including 
that it ‘reduces the need to identify pathogens by culturing respiratory tract samples’) but is 
relatively silent on how this will be undertaken and how data will be used to achieve the 
primary aims.  Biomarkers for pneumonia etiology (whether they be transcriptomic or 
other), while attractive conceptually, have many limitations, and their practical applicability 
at this point need careful scrutiny. I wonder whether the transcriptomic aspect of this study 
is an exploratory add-on (not in itself an invalid thing to do). I see no mention of power 
calculations with respect to the transcriptomic element, for instance, or how it will be 
integrated into the analysis as a whole. 
Action/Answer: The reviewer is right: transcriptomics is an add-on, as we have clearly 
stated that “Patient enrollment began in November 2016” and that “Sampling for 
transcriptomics was initiated in May 2017” (i.e. 7 months after the initiation of the study). 
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Therefore, the overall study has not been powered to meet this secondary objective. 
In order to clarify these points, we added the following sentence in the chapter related to 
Data management and analysis: “Etiologic fractions will be also computed from 
transcriptomics data, independently from calculations from microbiological data, and 
compared with each other.” 
 
Comment: The power calculation description is restricted to the primary objective. It would 
be helpful to show that there is adequate power for all objectives. 
Action/Answer: The study has been powered for the primary objective only, and the 
uncertainty around the values corresponding to secondary objectives will be provided by 
95% confidence intervals. We added the following sentence in Data management and 
analysis: “Ninety-five-percent confidence intervals will be calculated, with regards to the 
outcomes linked to the primary and secondary objectives.” 
 
Comment: The analytic methods planned for the primary objective are fairly restricted.  I 
would encourage the authors to learn from the approaches taken in studies such as PERCH 
and get the most they can out of the data. This can still be done even though recruitment 
has been completed. 
Action/Answer: Methodologies such as partially latent class models (if this is what Dr 
Howie refers to) have been considered for PEARL study. Nevertheless, they can poorly be 
applied to our dataset given the restricted range of samples in our study: nasopharyngeal 
swab mainly, some sputum, and blood cultures -that are expected to have a low yield in 
primary health care and will therefore be poorly informative. In comparison with PERCH, 
where information from a much wider range of biological samples taken from severe cases 
was used, our dataset would be poorly suitable for complex models. Another drawback of 
PLC models is that they appear as a ‘blackbox’ while Population Attributable Fraction, 
resulting from Generalized Linear Models, are much more straightforward and 
comprehensible.   
 
Comment: There is no mention of using a point-of-care testing approach except at the end 
of the objectives and I wonder what was meant by that. 
Action/Answer: Actually, the PoC tests will be performed in laboratories located nearby but 
not in the institution where the patients will be included.  The results are therefore not 
become available real time and cannot be considered true PoC tests. 
 
Comment: The case definition used was not explicitly linked to the WHO definition, but 
reference was made to using WHO categorisation of severity.   Clarifying the relationship 
between study and WHO definitions would be helpful.  
Action/Answer: Exact. We added the following sentence in Inclusion criteria: “The case 
definition of CAP was based on the WHO’s IMCI. “ 
 
Comment: What does the protocol mean when it says that inclusion requires “no wheezing 
suggestive of asthma at auscultation”? What sort of wheezing is that? Does ‘suggestive’ 
mean age, history, trial of bronchodilator, or something else?  
Action/Answer: The reviewer is correct. This is indeed not clear. We added the following 
sentence in Inclusion criteria: “Characteristics of wheezing suggestive of asthma included: 
expiratory wheezing, high pitched wheezing, wheezing with history of asthma and without 
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fever nor history of fever, and any clinical picture such as the clinician would exclude LRTI 
and retain asthma as final diagnostic.” 
 
Comment: What does the protocol mean when it specifies “particular attention to 
pneumonia with a breathing rate > 50 breaths per minute’? Was this a de facto entry 
criterion? 
Action/Answer: No, it just means that we measured the breathing rate twice in children, in 
order to evaluate its pertinence in our own dataset. In the manuscript, we therefore 
changed the sentence as follows: “Moreover, in children under five years of age, we will 
assess the breathing rate twice, since it has been shown that the cut-off of > 50 breaths per 
minute, assessed twice, is more specific for pneumonia than the standard IMCI 
recommendations for children 1–5 years old (40 breaths/min), and was successfully adopted 
in the ALMANACH protocol.” 
 
Comment: What does the protocol mean when it says that ‘relevant’ results will be 
communicated to clinicians. Which are these? Did you share NP or sputum PCR results and if 
so how did you suggest that clinicians interpret them? 
Action/Answer: The criteria for feedback of individual lab data, as specified in the protocol 
shared with laboratories, included:
Identification of clinically relevant bacteria in blood (e.g. no bacteria associated to 
skin contamination, like coagulase-negative Staphylococci), by conventional 
microbiology or molecular tools. Information of identification and AST results will 
both be reported to the clinician by phone as soon as they will become available.
○
Identification of clinically relevant bacteria in nasopharyngeal swab or sputum of CAP 
cases, by conventional microbiology or molecular tools. This includes detection of 
atypical bacteria (Chlamydia pneumoniae or Mycoplasma pneumoniae) by BioFire. 
Information related to the identification and AST results will be reported by phone to 
the clinician as soon as they become available.
○
Identification of RSV in infants (cases or controls) aged ≤12 months.○
Positive Binax test in urine of case.○
This was added to the manuscript, in the chapter Analysis of biological samples. 
 
Comment: The protocol appears to state that 6ml of blood will be taken for blood culture. 
Even in infants? The sample collection protocols requires clarification here. 
Action/Answer: No, in infants and small children, the volume of blood taken was lower. The 
following sentence has been added to clarify this: “The target blood volume for blood 
culture is 1-3 mL in under-fives and 6 mL in children aged five or above and in adults, 
following manufacturers’ recommendations.”  
Competing Interests: No competing interests were disclosed.
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© 2018 Page A. This is an open access peer review report distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited.
Anne-Laure Page  
Epicentre, Paris, France 
This manuscript describes the study protocol for a study on the etiology of pneumonia among 
refugees and local population in Lebanon. The study, which has already completed all inclusions, 
was designed to investigate the population-attributable fractions (PAF) of specific viral and 
bacterial pathogens by comparing the proportion of pathogens detected by culture, PCR and rapid 
tests among pneumonia cases and age-matched controls. In addition, it aims at describing the 
pathogens isolates (antimicrobial susceptibility and serotypes if applicable), identifying risk factors 
for pneumonia and providing transcriptomics data to identify expression patterns associated with 
specific pathogens. The manuscript is clear and well written and describes the study adequately, 
except for some areas, which would require additional information:  
Describe the recommended volumes of blood collection for blood culture according to the 
age
1. 
The study sites are primary healthcare facility (no hospital facility), but some of the inclusion 
criteria (in particular chest indrawing in children < 3 years of age) would require immediate 
referral to hospital. Please describe how inclusions are performed for these patients.
2. 
Describe the rationale for having gastrointestinal infections as exclusion criteria for 
controls.
3. 
The sample size calculation is stratified by age group (150 patients for each of four age 
groups), leading to a final sample size of minimum 600 cases and maximum 900 cases. It 
would be helpful to know what were the expected proportions of patients in each age group 
to understand the final sample size calculation. The authors could comment on the fact that 
finally 1420 patients were included, which is not consistent with the initial sample size 
calculated.
4. 
More information could be provided on the culture of bacterial from respiratory samples 
(sputum samples and nasopharyngeal swabs). Is quality of the sputum and absence of 
saliva contamination assessed? Which selective media are used?
5. 
Please provide more information about transcriptomics analysis (at least a reference).6. 
The references cited for the semi-quantitative multiplex real-time PCR assay to detect S. 
pneumoniae, S. aureus and H. influenzae B do not provide sufficient information on the 
method. Authors should also describe more in details how this assay is performed on EDTA 
whole blood (volume of blood used for extraction and in the PCR assay). Interpretation of 
the PCR results from blood, sputum and nasopharyngeal swabs should also be described, in 
particular if there is a threshold (in Ct or copies/mL) used to consider the result as positive.
7. 
It is unclear whether the additional indicators described in the study outcomes would come 
from the study results or from other sources. Some, like clinical signs of CAP, can be 
analysed from the study data, whereas others, while for others, like agent-specific 
hospitalization and fatality rates, the corresponding data is not collected in the CRF.
8. 
The primary objective states that the PAFs will be estimated “using a combination of 
conventional methods and transcriptomics”, but it is unclear in the analysis plan if or how 
the transcriptomics data will be used to determine the PAFs and how these transcriptomics 
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Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Partly
Are the datasets clearly presented in a useable and accessible format?
Not applicable
Competing Interests: No competing interests were disclosed.
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
Author Response 01 Mar 2019
Thomas Kesteman, Fondation Mérieux, Lyon, France 
We would like to express thanks the reviewer for her useful comments and suggestions. We 
carefully reviewed her report and we changed the manuscript according to her 
propositions. These changes included adding the complete methodology of a triplex PCR 
that had not been disclosed in a previous scientific article. Therefore, we added M Stéphane 
Pouzol, who designed and developed that technique, as an author of the present 
manuscript. Our answers to her questions and comments are listed in the text below. 
 
Comment: Describe the recommended volumes of blood collection for blood culture 
according to the age. 
Action/Answer: The following sentence has been added to clarify this: “The total volume of 
blood taken is 0.5-1.0 mL in controls of all ages and, in cases, 2.5-5.0 mL in infants (<1 year 
old), 3.5-6.0 mL in children aged one to four, 10.5-17.0 and 6 mL in children aged five or 
above, and 18.5-19.0 mL in adults (≥18 years old), with a flexibility in the age cut-off 
depending on the individual’s weight and overall health status.” 
 
Comment: The study sites are primary healthcare facility (no hospital facility), but some of 
the inclusion criteria (in particular chest indrawing in children < 3 years of age) would 
require immediate referral to hospital. Please describe how inclusions are performed for 
these patients. 
Action/Answer: We added the following in Study setting and design: “After enrolment in the 
study, patients will be managed as per local guidelines and doctors’ recommendations; in 
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Comment: Describe the rationale for having gastrointestinal infections as exclusion criteria 
for controls. 
Action/Answer: We added the following in Inclusion criteria - Controls and provided a 
reference: “Individuals with gastro-intestinal symptoms were excluded as some viruses 
(adenovirus, enterovirus, and coronavirus) are proven or suspected to cause either 
respiratory or gastro-intestinal symptoms, and including such patients as controls would 
result in an underestimation of the attributable fraction of these pathogens.” 
 
Comment: The sample size calculation is stratified by age group (150 patients for each of 
four age groups), leading to a final sample size of minimum 600 cases and maximum 900 
cases. It would be helpful to know what were the expected proportions of patients in each 
age group to understand the final sample size calculation. 
Action/Answer: At the moment of protocol design, there were no data available regarding 
incidence of lower respiratory tract infection in the different age groups. We assume that 
will would include an approximately equal number of cases in each of the four age groups. 
Hence, 150*4 = 600. 
 
Comment: The authors could comment on the fact that finally 1420 patients were included, 
which is not consistent with the initial sample size calculated. 
Action/Answer: Actually, this is a result of the study, and that should not have appeared in 
the protocol. Therefore, we removed that sentence. It will be discussed in the manuscript 
presenting the results of the study. 
 
Comment: More information could be provided on the culture of bacterial from respiratory 
samples (sputum samples and nasopharyngeal swabs). Is quality of the sputum and 
absence of saliva contamination assessed? Which selective media are used? 
Action/Answer: We agree with the reviewer’s comment. We modified the manuscript as 
follows: “Sputum samples and STGG media will be inoculated onto different selective agar 
plates according to standard laboratory procedures (at least one blood culture medium, one 
chocolate agar, and one medium selective for gram-negative bacilli) and incubated under 
specific conditions (37°C, aerobic atmosphere supplemented with CO2) to determine the 
presence of respiratory pathogens and assess antibiotic susceptibility. Quality of sputum 
and absence of contamination by saliva will be assessed by standard laboratory 
procedures.” 
 
Comment: Please provide more information about transcriptomics analysis (at least a 
reference). 
Action/Answer: Done. The Transcriptomics paragraph of Analysis of biological samples 
chapter and the Data management and analysis chapter have been substantially 
supplemented to include all procedures related to transcriptomics, and we added 
references to articles where those methods have been used. 
 
Comment: The references cited for the semi-quantitative multiplex real-time PCR assay to 
detect S. pneumoniae, S. aureus and H. influenzae B do not provide sufficient information 
on the method. 
Action/Answer: We amended references and added the information required for 
performing the PCR in the Molecular biology testing of respiratory samples paragraph of 
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Analysis of biological samples chapter: sequences of primers, probes, reagents, and 
temperature cycle. 
 
Comment: Authors should also describe more in details how this assay is performed on 
EDTA whole blood (volume of blood used for extraction and in the PCR assay). 
Action/Answer: Done. The Detection of bacteria in blood paragraph of Analysis of biological 
samples chapter has been modified as follows: “Whole blood (200 μL EDTA) samples from all 
cases will be extracted using QIAamp DNA blood mini kit (Qiagen, Hilden, Germany), and 
the same semi-quantitative multiplex Real-Time PCR assay as for respiratory samples will be 
conducted on 5 μL of extracted DNA to identify Streptococcus pneumoniae, Staphylococcus 
aureus and Haemophilus influenzae B.” 
 
Comment: Interpretation of the PCR results from blood, sputum and nasopharyngeal 
swabs should also be described, in particular if there is a threshold (in Ct or copies/mL) used 
to consider the result as positive. 
Action/Answer: Done. The following sentence has been added in Molecular biology testing 
of respiratory samples paragraph of Analysis of biological samples chapter: “Amplification 
curves will be examined individually by two independent technicians, at the local laboratory 
and at the Laboratoire des Pathogènes Emergents (Lyon, France). Cycle thresholds (Ct) 
value will be manually set so that it intersects the exponential curve at its inflexion point. 
Any exponential signal observed between 0 and 40 Ct value will be considered as positive.” 
 
Comment: It is unclear whether the additional indicators described in the study outcomes 
would come from the study results or from other sources. Some, like clinical signs of CAP, 
can be analysed from the study data, whereas others, while for others, like agent-specific 
hospitalization and fatality rates, the corresponding data is not collected in the CRF. 
Action/Answer: Agree. The following sentence has been added in Other data collected: “A 
subgroup of patients or parents/legal guardians, randomly selected, was called back at least 
one month after inclusion to re-evaluate the outcome of included cases (hospitalization, 
death).” 
 
Comment: The primary objective states that the PAFs will be estimated “using a 
combination of conventional methods and transcriptomics”, but it is unclear in the analysis 
plan if or how the transcriptomics data will be used to determine the PAFs and how these 
transcriptomics data will be analysed. 
Action/Answer: Agree. This is indeed misleading. We removed this part of the sentence in 
the primary objective and added the following secondary objective: “compare 
microbiological and transcriptomic methods in estimating viral vs bacterial attributable 
fractions of LRTI”.  
Competing Interests: No competing interests were disclosed.
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